Beam Glb: Q3 Earnings Insights

Beam Glb (NASDAQ:BEEM) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:05 AM. Here’s what…

Beam Glb (NASDAQ:BEEM) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:05 AM.

Here’s what investors need to know about the announcement.

Earnings

Beam Glb beat estimated earnings by 18.75%, reporting an EPS of $-0.26 versus an estimate of $-0.32.

Revenue was up $9.88 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.02 which was followed by a 5.83% drop in the share price the next day.

Here’s a look at Beam Glb’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.34 -0.42 -0.41 -0.24
EPS Actual -0.32 -0.38 -0.77 -0.67
Revenue Estimate 15.00M 8.28M 7.56M 4.08M
Revenue Actual 17.82M 13.02M 7.90M 6.61M

To track all earnings releases for Beam Glb visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Signify Health: Q2 Earnings Insights

Signify Health (NYSE:SGFY) reported its Q2 earnings results on Wednesday, August 3, 2022 at 05:00 PM. Here's what investors need to know about the announcement. Earnings Signify Health beat estimated earnings by 750.0%, reporting an EPS of $0.85 versus an estimate of $0.1.

SGFY

Read More

Celularity Announces Net Sales And Total Revenue Expectations; Expects Net Sales Of Its Biomaterial Products And Biobanking Businesses To Be In The Range Of $11.4M-$12.1M For Q4 2023 And $22.06M-$22.76M For FY23

Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year

CELU